Table 1 Baseline characteristics.
Characteristic | Etanercept | Infliximab | Adalimumab | Anakinra | Biologics total | Control |
|---|---|---|---|---|---|---|
N | 397 | 255 | 121 | 45 | 818 | 265 |
Age | 53.2 (12.5) | 54.0 (12.3) | 53.8 (12.4) | 56.2 (11.2) | 53.7 (12.3) | 57.4 (10.3) |
Female (%) | 79.1 | 71.0 | 85.1 | 73.3 | 76.6 | 83.8 |
Disease duration (years), median (IQR) | 10 (6–18) | 9 (5–14) | 12 (7–19) | 13 (7–21) | 10 (6–17) | 9 (5–17) |
Rheumatoid factor positive (%) | 82.1 | 83.5 | 84.3 | 77.8 | 82.2 | 77.7 |
Swollen joint count | 10.2 (6.2) | 11.3 (6.4) | 9.6. (6.4) | 10.9 (6.6) | 10.5 (6.3) | 8.2 (5.3) |
Tender joint count | 13.0 (7.3) | 13.0 (7.4) | 12.3 (7.4) | 13.6 (7.3) | 12.9 (7.3) | 10.5 (6.9) |
ESR (mm/h), median (IQR) | 33 (20–54) | 32 (18–54) | 30 (17–44) | 36 (22–51) | 32 (18–53) | 23 (14–37) |
CRP (mg/l), median (IQR) | 20 (7–42) | 18 (7–48) | 18 (7–32) | 21 (6–36) | 18 (7–42) | 12 (4–27) |
DAS28 | 6.1 (1.1) | 6.2 (1.2) | 5.9 (1.2) | 6.3 (1.0) | 6.1 (1.1) | 5.5 (1.1) |
FFbH | 53.4 (22.9) | 52.8 (20.9) | 53.2 (25.1) | 52.7 (23.3) | 53.1 (22.8) | 61.4 (22.4) |
Number of previous DMARDs | 3.9 (1.3) | 3.9 (1.4) | 4.4 (1.3) | 4.3 (1.6) | 4.0 (1.4) | 2.8 (0.9) |
Current treatment DMARD (%) | ||||||
MTX alone | 33.0 | 67.5 | 43.0 | 60.0 | 46.7 | 1.5 |
Other single DMARD | 11.9 | 14.5 | 8.3 | 8.8 | 12.0 | 29.8 |
Combination of two DMARDs | 5.3 | 8.6 | 5.8 | 4.4 | 6.4 | 57.3 |
Combinations of three DMARDs | 1.3 | 1.6 | 1.6 | 0.0 | 1.3 | 11.3 |
No DMARD | 48.6 | 7.8 | 41.3 | 26.7 | 33.6 | 0 |
Biologic dose/week (mg)a | 49.7 (4.1) | 4.0 (1.9) | 21.5 (7.0) | 700 (0) | - | - |
Comorbidity (%) | 72.6 | 68.5 | 64.5 | 71.1 | 70.0 | 72.8 |
Osteoporosis (%) | 30.2 | 27.9 | 22.3 | 35.6 | 28.6 | 18.5 |